Targeted integration of a DNA transposon-based nonviral vector

基于 DNA 转座子的非病毒载体的靶向整合

基本信息

  • 批准号:
    8237293
  • 负责人:
  • 金额:
    $ 48.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-01-01 至 2016-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Gene therapy has the potential to permanently correct or prevent monogenic disorders such as cystic fibrosis. We have a demonstrated track record of utilizing many categories of viral and non-viral vectors to deliver genes to the airways; however, choosing the best gene therapy vector leads to a very significant dilemma. Non-integrating vectors may not persist and integrating vectors may cause insertional mutagenesis. There is a critical need for improved gene delivery tools that address this conundrum. Our long-term goal is to engineer a vehicle for gene delivery to cells that is a safe and effective therapeutic for cystic fibrosis. To this end, the goal for these proposed studies is to develop an integrating vector with a predictable integration pattern that targets 'safe harbor' genomic loci. Nonviral vector systems are used increasingly as tools for gene transfer applications. We successfully used the piggyBac DNA transposon system as an effective integrating vector for gene transfer. Method. Based on our preliminary studies, piggyBac transposase is amenable to modification. Furthermore, recent advances in the ability to engineer customized zinc finger proteins make the possibility of targeted transposition promising as a therapeutic approach. The overall hypothesis is that the piggyBac transposon system may be modified to retarget integration. We will use multiple approaches to direct the piggyBac transposase to designated loci, increase vector delivery efficiency, and improve the utility and safety of the vector for gene therapy. Here we propose to: 1) generate and validate the function of 'safe harbor' zinc finger protein/piggyBac transposase fusion proteins; 2) map zinc finger protein/piggyBac transposase mediated transposon integrations in the genome; and 3) create a hybrid piggyBac/lentivirus vector system to improve delivery efficacy. These studies will provide important mechanistic information regarding the motifs important for directing piggyBac integrations. PUBLIC HEALTH RELEVANCE: The successful completion of these studies will bring us closer to the long-term goal of correcting the cystic fibrosis genetic deficiency. The specific goal of this project is to create a targetable transposon vector system for therapeutic gene transfer applications. Successful site-restricted transgene integration into human genomic DNA would have exciting and broad applications to the fields of gene therapy and molecular genetics.
描述(由申请人提供):基因治疗有可能永久纠正或预防单基因疾病,如囊性纤维化。我们已经证明了利用许多类别的病毒和非病毒载体将基因递送到气道的记录;然而,选择最好的基因治疗载体导致了一个非常重大的困境。非整合载体可能不会持续存在,而整合载体可能导致插入诱变。迫切需要改进的基因递送工具来解决这个难题。我们的长期目标是设计一种将基因递送到细胞的载体,这是一种安全有效的囊性纤维化治疗方法。为此,这些研究的目标是开发具有可预测整合模式的整合载体,其靶向“安全港”基因组基因座。非病毒载体系统越来越多地用作基因转移应用的工具。我们成功地使用piggyBac DNA转座子系统作为一个有效的整合载体的基因转移。法基于我们的初步研究,piggyBac转座酶是适合修饰的。此外,最近的进展,在工程定制的锌指蛋白的能力,使靶向转座有希望作为一种治疗方法的可能性。总的假设是piggyBac转座子系统可以被修饰以重新靶向整合。我们将使用多种方法将piggyBac转座酶定向到指定位点,提高载体递送效率,并提高载体用于基因治疗的实用性和安全性。在此,我们建议:1)产生并验证“安全港”锌指蛋白/piggyBac转座酶融合蛋白的功能; 2)绘制基因组中锌指蛋白/piggyBac转座酶介导的转座子整合;和3)创建杂合piggyBac/慢病毒载体系统以改善递送功效。这些研究将提供重要的机制信息的图案重要的指导piggyBac整合。 公共卫生相关性:这些研究的成功完成将使我们更接近纠正囊性纤维化遗传缺陷的长期目标。该项目的具体目标是创建一个靶向转座子载体系统的治疗基因转移应用。成功地将定点转基因整合到人类基因组DNA中将在基因治疗和分子遗传学领域具有令人兴奋和广泛的应用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICK L SINN其他文献

PATRICK L SINN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICK L SINN', 18)}}的其他基金

Spread and Release of Measles in the Airways
麻疹在呼吸道中的传播和释放
  • 批准号:
    10190793
  • 财政年份:
    2018
  • 资助金额:
    $ 48.21万
  • 项目类别:
Spread and Release of Measles in the Airways
麻疹在呼吸道中的传播和释放
  • 批准号:
    10408155
  • 财政年份:
    2018
  • 资助金额:
    $ 48.21万
  • 项目类别:
Life-long phenotypic correction of CF airways
CF 气道的终生表型校正
  • 批准号:
    10653542
  • 财政年份:
    2017
  • 资助金额:
    $ 48.21万
  • 项目类别:
A Hybrid Viral/Nonviral Vector for CFTR Delivery to CF Pig Airways
用于 CFTR 递送至 CF 猪气道的混合病毒/非病毒载体
  • 批准号:
    9923461
  • 财政年份:
    2017
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted integration of a DNA transposon-based nonviral vector
基于 DNA 转座子的非病毒载体的靶向整合
  • 批准号:
    8598929
  • 财政年份:
    2012
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted integration of a DNA transposon-based nonviral vector
基于 DNA 转座子的非病毒载体的靶向整合
  • 批准号:
    8988595
  • 财政年份:
    2012
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted integration of a DNA transposon-based nonviral vector
基于 DNA 转座子的非病毒载体的靶向整合
  • 批准号:
    8403682
  • 财政年份:
    2012
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted Integration of a Lentiviral Vector
慢病毒载体的靶向整合
  • 批准号:
    7021573
  • 财政年份:
    2006
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted Integration of a Lentiviral Vector
慢病毒载体的靶向整合
  • 批准号:
    7170056
  • 财政年份:
    2006
  • 资助金额:
    $ 48.21万
  • 项目类别:
Targeted Integration of a Lentiviral Vector
慢病毒载体的靶向整合
  • 批准号:
    7337315
  • 财政年份:
    2006
  • 资助金额:
    $ 48.21万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 48.21万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了